title: Successful treatment of refractory bleeding after bridging from acute to chronic left ventricular assist device support with recombinant activated factor VII.
abstract: Cardiac surgery often is associated with a significant disruption of the coagulation system, particularly in high risk patients such as those undergoing placement of ventricular assist devices. This type of severe coagulopathy can lead to life threatening bleeding that can require massive transfusions to restore hemostasis. Recently, recombinant activated factor VII (rFVlla) has been +used as an alternative to massive transfusion for the treatment of refractory bleeding in several patient populations, including cardiac surgery patients. In the case reported here, the patient's risk was compounded by multiple operations in a short period of time and circulatory collapse that was initially managed with a shortterm left ventricular assist device. After multiple failed attempts at weaning the patient from circulatory assistance, he was taken back to the operating room for conversion to a chronic, implantable device. This procedure was complicated by a severe coagulopathy secondary to a myriad of factors commonly encountered after the use of cardiopulmonary bypass. The administration of rFVlla resulted in a rapid cessation of bleeding without thrombotic complications. This is the first case reported involving an acute to chronic bridge patient. Despite the anecdotal success of rFVlla, further clinical research is needed to establish both the safety and economic feasibility of this agent.
authors.affiliation: University of Kentucky Chandler Medical Center, Pharmacy Services, Lexington, KY 40536-0293, USA.
authors.forename: Jeremy D
authors.initials: JD
authors.lastname: Flynn
authors.forename: Phillip C
authors.initials: PC
authors.lastname: Camp
authors.forename: M Salik
authors.initials: MS
authors.lastname: Jahania
authors.forename: Chand
authors.initials: C
authors.lastname: Ramaiah
authors.forename: Wendell S
authors.initials: WS
authors.lastname: Akers
mesh_terms: D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D005167:Factor VII / Q000627:therapeutic use*; D006353:Heart-Assist Devices; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D005167:Factor VII